Literature DB >> 15014136

Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization.

Mary J Clark1, Richard R Neubig, John R Traynor.   

Abstract

Chronic mu-opioid agonist treatment leads to dependence with withdrawal on removal of agonist. At the cellular level withdrawal is accompanied by a supersensitization of adenylyl cyclase, an effect that requires inhibitory Galpha proteins. Inhibitory Galpha protein action is modulated by regulator of G protein signaling (RGS) proteins that act as GTPase activating proteins and reduce the lifetime of Galpha-GTP. In this article, we use C6 glioma cells expressing the rat mu-opioid receptor (C6mu) to examine the hypothesis that Galphao alone can mediate mu-opioid agonist induced adenylyl cyclase supersensitivity and that endogenous RGS proteins serve to limit the extent of this supersensitization. C6mu cells were stably transfected with pertussis toxin (PTX)-insensitive Galphao that was either sensitive or insensitive to endogenous RGS proteins. Cells were treated with PTX to uncouple endogenous Galpha proteins followed by exposure to the mu-opioid agonists [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin or morphine. Supersensitization was observed in cells expressing wild-type Galpha, but this was lost on PTX treatment. In cells expressing PTX-insensitive Galphao supersensitization was recovered, confirming that Galphao alone can support supersensitization. In cells expressing the RGS-insensitive mutant Galphao, there was a greater degree of supersensitization and the concentration of micro-agonist needed to achieve half-maximal supersensitization was reduced by 10-fold. The amount of supersensitization seen did not directly relate to the degree of acute inhibition of adenylyl cyclase. These results demonstrate a role for Galphao in adenylyl cyclase supersensitization after mu-agonist exposure and show that this action is modulated by endogenous RGS proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15014136     DOI: 10.1124/jpet.103.064824

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gnai2 allele.

Authors:  Xinyan Huang; Ying Fu; Raelene A Charbeneau; Thomas L Saunders; Douglas K Taylor; Kurt D Hankenson; Mark W Russell; Louis G D'Alecy; Richard R Neubig
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

Review 2.  Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction.

Authors:  K Defea
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

3.  Genome-Wide Small Interfering RNA Screening Reveals a Role for Cullin3-Really Interesting New Gene Ligase Signaling in Heterologous Sensitization of Adenylyl Cyclase.

Authors:  Zhong Ding; Karin F K Ejendal; Monica Soto-Velasquez; Michael P Hayes; Nicholas Santoro; Martha J Larsen; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2019-12-19       Impact factor: 4.030

4.  The complex of G protein regulator RGS9-2 and Gβ(5) controls sensitization and signaling kinetics of type 5 adenylyl cyclase in the striatum.

Authors:  Keqiang Xie; Ikuo Masuho; Cameron Brand; Carmen W Dessauer; Kirill A Martemyanov
Journal:  Sci Signal       Date:  2012-08-28       Impact factor: 8.192

5.  Detection of G protein-selective G protein-coupled receptor (GPCR) conformations in live cells.

Authors:  Rabia U Malik; Michael Ritt; Brian T DeVree; Richard R Neubig; Roger K Sunahara; Sivaraj Sivaramakrishnan
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

Review 6.  Regulators of G Protein Signaling in Analgesia and Addiction.

Authors:  Farhana Sakloth; Claire Polizu; Feodora Bertherat; Venetia Zachariou
Journal:  Mol Pharmacol       Date:  2020-05-30       Impact factor: 4.436

Review 7.  μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology.

Authors:  John Traynor
Journal:  Drug Alcohol Depend       Date:  2011-11-29       Impact factor: 4.492

8.  Regulators of G-Protein Signaling (RGS) Proteins Promote Receptor Coupling to G-Protein-Coupled Inwardly Rectifying Potassium (GIRK) Channels.

Authors:  Kylie B McPherson; Emily R Leff; Ming-Hua Li; Claire Meurice; Sherrica Tai; John R Traynor; Susan L Ingram
Journal:  J Neurosci       Date:  2018-08-27       Impact factor: 6.167

9.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

10.  Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.

Authors:  M F Divin; F A Bradbury; F I Carroll; J R Traynor
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.